Galenea Corp. Appoints Mark Benjamin as Chief Executive Officer
Galenea Corporation announced the appointment of Dr. Mark Benjamin as President and Chief Executive Officer.
Mark brings 16 years of experience in the pharmaceutical and biotech industries, including 13 years in business development. Prior to joining Galenea, Mark was the Chief Business Officer of Nura Inc., a neuroscience drug discovery company founded by 2004 Nobel laureate Dr. Linda Buck. Nura was acquired by Omeros Inc. in 2006. In previous positions, Mark served as Vice President of Global Business Development for Manteia SA, a Swiss-based subsidiary of Serono SA (now Merck KGaA) and was the senior business development executive at Rosetta Inpharmatics, a company founded by a team that included 2001 Nobel laureate Leland Hartwell. Rosetta was acquired by Merck & Company in 2001. Mark received a first class B.Sc. degree with honors from the University of London, and a D.Sc. degree in Cancer Biology from Harvard University.
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.